VC-backed Spero Therapeutics goes public
Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company focused on developing treatments for bacterial infections, has debuted its IPO after pricing its 5.5 million shares at $14 per share. Spero began trading on the NASDAQ under the ticker symbol “SPRO.” BofA Merrill Lynch, Cowen and Company LLC and Stifel are the lead underwriters. Spero’s backers include GV, RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.
2 November 2017•2 mins read
